Abstracts

Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy

Background The primary endpoints met in the REVIVE study have been previously reported, demonstrating the chemotherapeutic efficacy after the progression on NIVO therapy...

06/27/2022

Non-invasive HER2 status diagnosis in gastric cancer using surrogate DNA methylation markers

Background Gastric cancer (GC) is the fifth most common and fourth most lethal cancer worldwide. Unlike other cancer types, e.g., lung or breast cancer, very few targete...

06/27/2022

Characterization and management of cholangiocarcinoma in a tertiary hospital with a high volume of patients

Background The objective of this study is to evaluate the epidemiological characteristics, potential risk factors and local/systemic treatments in a tertiary care hospit...

06/27/2022

FOLFIRI or FOLFOX in second line of advanced biliary tract cancer: A retrospective analysis

Background Cholangiocarcinoma (CCA) are rare malignancies, globally accounting for 3% of upper gastrointestinal cancer. Despite recent advances in first-line treatment l...

M. Balarine ;

T. Felismino ;

M. Camandaroba ;

06/27/2022

A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma

Background For patients (pts) with HER2-overexpressing metastatic gastric cancer, trastuzumab + chemotherapy +/- pembrolizumab is a standard first-line option but only p...

06/27/2022

Phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: Cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer

Background Checkpoint inhibitor (CPI) monotherapy is ineffective for microsatellite stable colorectal cancer (MSS-CRC). NT-I7 (efineptakin alfa) is a long-acting IL-7 th...

06/27/2022

Efficacy and safety data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Real-world data from the non-interventional TACTIC study

Background In the pivotal phase III RECOURSE trial, trifluridine/tipiracil (FTD/TPI) significantly improved overall and progression-free survival (OS, PFS) in patients w...

06/27/2022

Estimating endpoint correlation between surrogate measures and overall survival using reconstructed survival data: Case studies from adjuvant and metastatic gastric cancer trials

Background Validation of intermediate endpoints such as disease-free survival (DFS) and progression-free survival (PFS) as surrogate predictors for overall survival (OS)...

06/27/2022

An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18)

Background BRAF inhibitor combination therapy became the standard of care for BRAF -mutated metastatic colorectal cancer (mCRC) based on the BEACON CRC trial, which show...

06/27/2022

Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol

Background Perioperative chemotherapy with FLOT constitutes a standard of care approach for locally advanced, resectable gastric or gastro-esophageal junction (GEJ) canc...

06/27/2022